February 13, 2012
Cellartis AB will be a partner in the 4DCellFate program, an EU-project aiming to better understand stem cell differentation
FEBRUARY 13, 2012, Gothenburg, Sweden
To develop a global understanding of the PRC and NuRD complexes in stem cell differentiation, in health and disease, the EU-project, 4DcellFate, aims to establish an integrated approach to explore the structure and function of the Polycomb Repressive Complexes (PRCs) and Nucleosome Remodelling and Deacetylation Complex (NuRD) in stem cell differentiation, and in cancer. Cellartis AB, Cellectis Stem Cells, will provide human embryonic stem cells (hESCs) to the program and will be involved in the development of methodologies for large scale proteomic analysis of the PRC and NuRD complexes during cell differentiation.
About Cellectis stem cells: Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Through the sharing of knowledge and expertise developed by the the two companies forming Cellectis stem cells - Cellartis and Ectycell – Cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace.
Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovations in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellartis.com.
About Cellectis : Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). To find out more, visit www.cellectis.com.